Compare Fiverr International Ltd (FVRR) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs McKesson Corporation — how do they compare? Fiverr International Ltd trades at $8.63 (market cap $310.61M), while McKesson Corporation trades at $930 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 349.2× Fiverr International Ltd's market cap, and McKesson Corporation pays a 0.4% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fiverr International Ltd for 62 Days and McKesson Corporation for 74 Days on average.
| FVRR | MCK | |
|---|---|---|
Market Cap | $310.61M | $108.46B |
Volume | 381,459 | 712,607 |
Sector | Media | Health |
52-Week High | $23.60 | $995.69 |
52-Week Low | $8.47 | $725.17 |
Typical Hold Time | 62 Days | 74 Days |
Enterprise Value | $63.00M | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.50, up 0.35% on the day, but has faced recent pressure with two consecutive quarterly earnings misses. The stock shows a bearish technical signal, with moving averages indicating a downtrend, while fundamentals reveal modest revenue growth to $430.91M in 2025 and a net income margin of 4.86%. Recent news highlights AI disruption compressing demand for freelance services, contributing to a 15% stock slump post-Q2 results.
The outlook remains cautious; while valuation ratios like P/E of 10.49 and P/S of 0.74 appear attractive, risks from AI competition and lowered 2026 guidance weigh on sentiment. Analyst consensus is a 'Hold' with a $10.50 price target, suggesting limited upside amid operational headwinds. Investors should balance cheap valuations against execution risks in a shifting gig economy.
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
